Aptose Biosciences (APTO) Downgraded by ValuEngine to Strong Sell
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Friday.
Several other research firms have also issued reports on APTO. Zacks Investment Research upgraded shares of Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Monday, August 14th. HC Wainwright upgraded shares of Aptose Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $1.00 to $4.00 in a research note on Thursday, September 7th. Roth Capital reiterated a “buy” rating and issued a $5.00 target price on shares of Aptose Biosciences in a research note on Monday, October 23rd. Finally, Canaccord Genuity set a $7.00 price target on shares of Aptose Biosciences and gave the company a “buy” rating in a research report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $4.50.
Aptose Biosciences (NASDAQ:APTO) traded down $0.02 during midday trading on Friday, hitting $2.01. 312,144 shares of the stock traded hands, compared to its average volume of 380,886. Aptose Biosciences has a 12-month low of $0.78 and a 12-month high of $2.30.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.